Key Highlights

  • Allogene shares are trading 6.50% higher at $1.31 on Wednesday, October 28, 2026, among the most active penny stocks.
  • Cash, equivalents and investments were $423.6 million on June 30, 2026, with a runway into 2029.
  • Cema-cel showed 58.3% MRD negativity versus 16.7% for observation in the April interim analysis.
  • The ALPHA3 trial plans to randomize about 220 patients, with enrollment complete by the end of 2027.
  • Short interest was 55.61 million shares, or 19.73% of float, with 9.71 days to cover.

Allogene Penny Stock Move: What Is Behind a 6.50% Gain Without a New Release?

Allogene Therapeutics (NASDAQ:ALLO) shares are trading 6.50% higher at $1.31 on Wednesday, October 28, 2026, which implies a prior close near $1.23 (calculated). No dated company release accompanied the move. The stock is among the most heavily traded penny stocks of the session.

The shares were down about 21% in October as of October 26, and the 52-week range runs from $1.04 to $4.46. At $1.31, the market value is about $453 million, calculated on 345.49 million shares.

Allogene is a clinical-stage company in South San Francisco developing allogeneic, or off-the-shelf, CAR T cell therapies for cancer and autoimmune disease.

Cema-Cel ALPHA3 Trial: How Strong Was the April Interim MRD Signal?

The main program is cemacabtagene ansegedleucel, known as cema-cel, in the pivotal ALPHA3 study of first-line consolidation for large B-cell lymphoma. The interim futility analysis, discussed on April 13, 2026, was triggered when the 24th patient completed the Day 45 minimal residual disease assessment.

MRD negativity was 58.3% (7 of 12 patients) in the cema-cel arm versus 16.7% (2 of 12) in the observation arm, a 41.6-point gap. The company cited literature suggesting a 25% to 30% difference could translate into meaningful clinical benefit at study completion. The company reported no treatment-related serious adverse events.

In July 2026 the FDA granted RMAT and Fast Track designations for first-line consolidation in high-risk disease. The sample is small.

Allogene Cash and Burn: Does $423.6 Million Fund the Pivotal Readout?

Allogene reported second-quarter results on August 12, 2026. Cash, cash equivalents and investments were $423.6 million on June 30, up from $258.3 million at December 31, 2025, and management guided to a runway into 2029.

The net loss was $42.7 million, or $0.13 per share, versus $50.9 million, or $0.23, a year earlier. Research and development expense was $30.7 million, general and administrative expense was $20.8 million, and collaboration revenue from a related party was $4.6 million.

For 2026, management guided to GAAP operating expenses of about $225 million, including roughly $35 million of non-cash stock compensation.

Allogene Short Interest: What Could 19.73% of Float Mean for the Move?

The latest short-interest data showed 55.61 million shares sold short, down from 59.60 million the prior month. That equals 16.10% of shares outstanding, 19.73% of float and 9.71 days to cover.

A large short position can amplify moves in either direction. Buying to close positions can add to a rally, while fresh selling can deepen a decline. The figure alone does not indicate direction.

What to Watch Next: What Do the Fourth-Quarter ALLO-329 Update and 2027 EFS Analysis Bring?

A clinical and translational update on ALLO-329, a dual CD19 and CD70 CAR T in the Phase 1 RESOLUTION study of lupus, scleroderma and inflammatory myositis, is expected in the fourth quarter of 2026. The company expects about 100 ALPHA3 sites by year-end, enrollment completion by the end of 2027, an interim event-free survival analysis in mid-2027 and the primary analysis in mid-2028.